HIGHLIGHTS
- who: Heng-Zhou Lai and colleagues from the Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China have published the article: Targeted Approaches to HER2-Low Breast Cancer: Current Practice and Future Directions, in the Journal: Cancers 2022, 3774 of /2022/
- how: Cohort 6 of the multicenter randomized IB/II BEGONIA study (ClinicalTrials.gov identifier NCT03742102) was designed to evaluate the potency of dovalizumab with T-DXD as a first-line treatment for HER2-low BC patients .
- future: From the perspective of chemotherapy benefit several clinical trials have found that HER2-low . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.